TEP1 and cancer: In patient P4, two of four malignant ascites-emerging clones may be targetable by inhibitors against BRAF (e.g. Vemurafenib), TEP1, ERBB4, PIK3CA, HDAC9, or FYN (Figure 5 and Supplementary Table 4).